Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PLC Systems -- Ignore unavailable to you. Want to Upgrade?

To: Dan Hughes who wrote (871)	5/8/1998 10:09:00 AM
From: GRC	Read Replies (1) \| Respond to of 1202

I wonder if the company has realized these type of announcements (new or old) seem to give the stock a boost? FRANKLIN, Mass., May 8 /PRNewswire/ -- PLC Systems Inc. (Amex: PLC - news) today announced that, at the 78th Annual Meeting of the Association of Thoracic Surgeons, clinicians from Boston, Massachusetts presented findings from a breakthrough study involving gene therapy and transmyocardial revascularization (TMR) using The Heart Laser System. Clinicians studied 29 pigs with artificially-induced diseased hearts displaying abnormal wall motion (wall motion is a determinant of the overall vitality of the heart muscle). Animals were assigned different treatment modalities including: no treatment, TMR only, gene therapy only and TMR in combination with direct injection of the gene, VEGF. Left ventricular free- wall motion was assessed by a cardiologist in a blinded (not informed of treatment modality) manner at six weeks after treatment. The TMR-gene therapy group displayed no evidence of wall motion abnormality post treatment. Researchers concluded that these results suggest that the combined use of TMR with direct injection of the gene, VEGF completely reverses ischemic (diseased) wall motion abnormalities in this animal model. William C. Dow President and CEO of PLC Systems stated, ''Both TMR using The Heart Laser System and gene therapy are exciting new therapies in the fight against coronary artery disease. Studies such as the research conducted in Boston continue to demonstrate TMR's potential therapeutic benefit not only as a sole therapy, but as a possible enhancement to other therapies such as VEGF. By combining the two therapies physicians may be able to provide patients a more complete revascularization than either therapy would alone.'' ''TMR using The Heart Laser System was recently recommended for approval by a Food and Drug Administration advisory panel, and we look forward to full clearance of our premarket approval application for The Heart Laser System,'' said Mr. Dow. TMR, or transmyocardial revascularization is a new surgical procedure for patients with chronic, severe coronary artery disease with no treatment alternative. The procedure has been performed on approximately 3,500 patients worldwide. Since TMR with The Heart Laser System is minimally invasive, recovery is generally quicker and less traumatic than open heart procedures. Generally, no blood transfusion is needed and, since the procedure is performed on a beating heart, there is no need for a heart-lung machine. PLC Systems Inc. is a cardiac revascularization company that is pioneering, developing and supplying the systems and components for TMR. The Company is investigating TMR as a technology with the potential to provide patients suffering from coronary artery disease an adjunct to angioplasty and coronary bypass graft surgery. PLC Medical Systems, Inc., a wholly owned subsidiary of PLC Systems Inc., has developed the CO2 Heart Laser System for TMR, which uses PLC's patented 'heart-synchronized pulsed laser' technology. Note: Certain of the above statements may be forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of factors, including competitive developments, regulatory approval requirements, the ability to convince health care professionals and third party payers of the medical and economic benefits of The Heart Laser System, and the risk factors described in the Company's annual report, SEC Form 10K for fiscal year ended December 31, 1997, and the company's other SEC reports.

To: Dan Hughes who wrote (871)	5/8/1998 11:43:00 AM
From: John F. Dowd	Respond to of 1202

Dear Dan: I was just kidding of course and I do appreciate your thoughtful insights into this TMR subject. Lord knows that on the Yahoo board there is very little of substance ever mentioned although burnthru and cardiohands are excellent contributors as are you. The following article is just another shot across the shorts bow. This stock like others I have owned and own is in the precarious position of similar to a woman about o give birth and the shorts are the abortionists. They are hoping to turn the corner and those that hang in there will be well rewarded when the gestation period is ended fruitfully. Yuri was a similar stock in a differet industry as is OCOM and Schick Tecnologies. Altruism aside the question must be asked which ones are worth the wait. Which one is going to be the next MSFT in its field? Regards, John PR Newswire, Friday, May 08, 1998 at 09:18 FRANKLIN, Mass., May 8 /PRNewswire/ -- PLC Systems Inc. (AMEX:PLC) today announced that, at the 78th Annual Meeting of the Association of Thoracic Surgeons, clinicians from Boston, Massachusetts presented findings from a breakthrough study involving gene therapy and transmyocardial revascularization (TMR) using The Heart Laser System. Clinicians studied 29 pigs with artificially-induced diseased hearts displaying abnormal wall motion (wall motion is a determinant of the overall vitality of the heart muscle). Animals were assigned different treatment modalities including: no treatment, TMR only, gene therapy only and TMR in combination with direct injection of the gene, VEGF. Left ventricular free- wall motion was assessed by a cardiologist in a blinded (not informed of treatment modality) manner at six weeks after treatment. The TMR-gene therapy group displayed no evidence of wall motion abnormality post treatment. Researchers concluded that these results suggest that the combined use of TMR with direct injection of the gene, VEGF completely reverses ischemic (diseased) wall motion abnormalities in this animal model. William C. Dow President and CEO of PLC Systems stated, "Both TMR using The Heart Laser System and gene therapy are exciting new therapies in the fight against coronary artery disease. Studies such as the research conducted in Boston continue to demonstrate TMR's potential therapeutic benefit not only as a sole therapy, but as a possible enhancement to other therapies such as VEGF. By combining the two therapies physicians may be able to provide patients a more complete revascularization than either therapy would alone."